Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612311 · ClinicalTrials.gov registry record · Phase 3
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 603
- Enrollment target
NCT02612311 is a Phase 3 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 603 participants.
The verdict
NCT02612311, a Phase 3 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 603 participants
- Enrollment target
Study Summary
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.
Interventions
- BIOLOGICAL Obinutuzumab
- BIOLOGICAL Ublituximab
- DRUG TGR-1202
- DRUG Chlorambucil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2023-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612311
The ClinicalTrials.gov registry entry for NCT02612311 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT02612311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612311 about?
NCT02612311 is a clinical study titled "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia". This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.
What is the current status of trial NCT02612311?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 603 participants. The study started on 2015-11-19. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT02612311?
The interventions under investigation include: Obinutuzumab (BIOLOGICAL), Ublituximab (BIOLOGICAL), TGR-1202 (DRUG), Chlorambucil (DRUG).
Who is sponsoring clinical trial NCT02612311?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.